Welcome to our dedicated page for ProKidney SEC filings (Ticker: PROK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProKidney Corp. filings document a late clinical-stage biotechnology issuer focused on rilparencel, an autologous renal cell therapy candidate for chronic kidney disease in patients with diabetes. Recent Form 8-K reports furnish operating and financial results, Regulation FD investor presentations, clinical-study and development-plan updates, FDA-pathway disclosures, financial-position information, and material-event or material-agreement disclosures.
Proxy materials describe annual meeting proposals, board elections, auditor ratification, stockholder voting procedures, and governance matters for the public company.